INTRODUCTION
The impact of the new ACC/AHA hypertension guideline 1 in primary care is uncertain. We describe implications of the guideline for: (1) patients with diagnosed hypertension in a diverse regional health improvement collaborative (RHIC) and (2) patients without diagnosed hypertension at one safety-net health system within the RHIC.
METHODS
We used data from Better Health Partnership (BHP), a Northeast Ohio RHIC that includes 80 primary care clinics across nine health systems.
2 BHP member clinics use electronic health record data to report blood pressure (BP) results twice yearly for patients with hypertension using the last BP in the reporting period. In the full sample of hypertensive patients, BHP measures blood pressure control in two ways: (1) BP < 140/90 mmHg for most, and BP < 150/90 for those over age 60 without diabetes (based on Joint National Committee (JNC) 8 guidelines) 3 and (2) BP < 140/90 mmHg for all patients (based on JNC 7). 4 In the second sample of patients without hypertension, we identified all patients with ≥ 2 visits over a 2-year period at any of 20 primary care clinics at MetroHealth, a safety-net system in Cleveland that also participates in BHP. For those without a hypertension diagnosis, we determined how many would be diagnosed with hypertension using a BP reading of ≥ 130/80 mmHg measured at two consecutive primary care visits. We ascertained whether medications would be recommended for newly diagnosed patients based on the presence of diabetes, chronic kidney disease or a 10-year cardiovascular risk score ≥ 10% using the pooled cohort equation. 5 If the risk score could not be calculated, we assumed a low (< 10%) risk.
RESULTS
There were 194,742 hypertensive patients seen by 813 providers at 80 primary care clinics between July 1, 2016 and June 30, 2017. Clinic-level characteristics range from 0 to 63% Medicaid patients, 0 to 98% black patients, and 0 to 48% patients who prefer speaking Spanish. In this sample, 84% received at least one BP medication, 61% received at least two BP medications, and 39% received three or more BP medications. Using the current BHP BP targets, 79% and 74% had good BP control using the JNC8 and JNC7 guidelines, respectively (Fig. 1) . Using the ACC/AHA guideline BP control target (BP < 130/80 mmHg), the proportion with good BP control would decrease to 35% (Fig. 1) . In the second sample, there were 57,818 of 107,921 patients without an established diagnosis of hypertension. Patients seen at MetroHealth are diverse, with 30% Medicaid, 7% uninsured, 30% Medicare, 33% commercial insurance, 52% white, 37% black, 5% , and a median household income of $40,099. Based on the ACC/AHA guideline, 19,776 new patients would be diagnosed with hypertension, increasing the overall prevalence of hypertension by 19%, from 46% (n = 50,103) to 65% (n = 69,879) (Fig. 2) . In addition, 5129 newly diagnosed patients with hypertension would receive a recommendation to start medication, increasing the proportion of total primary care patients (N = 107,921) on BP medications by 4.7% (from 40.9 to 45.7%).
DISCUSSION
Our study is the first to use real-world blood pressure measurement when considering implications of the new ACC/ AHA hypertension guideline. Adoption of the ACC/AHA hypertension guideline would meaningfully increase the number of persons identified with hypertension, decrease the percentage of hypertension patients under good BP control, and add significant medication burden. While these findings are not surprising, it is important to recognize the magnitude of potential changes when deciding on quality targets. Our regional results demonstrate a higher percentage of patients who would be identified as hypertensive and a higher percentage who would be recommended a BP medication compared with national estimates from the recently reported National Health and Nutrition Examination Survey (NHANES) data. 6 Using NHANES, Munter et al. reported an additional 13.7% of people diagnosed with hypertension and an additional 1.9% who would require medication treatment based on the ACC/ AHA guideline versus the additional 19 and 4.7% we found respectively in our region. 6 The differences between our results may be due to a variety of factors including differences in patient populations (regional versus national) or in methods for BP measurement (real world versus study protocol) between the two studies. We encourage others to review their data to better determine local policy and clinical implications of instituting different quality targets. We also encourage future research on the effect of the new guideline on provider engagement, patient adherence, patient quality of life, and clinical outcomes.
